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a b s t r a c t
Instead of relying on drugs to reduce the parasite burden of leishmaniasis, and waiting for
the effector immune response to develop in time to control the parasites, immunotherapy
in conjunction with chemotherapy can rapidly induce the effector immune response.
With a safe and potent drug plus an affordable therapeutic vaccine (immunostimulant),





leishmaniasis might be sufﬁcient to induce a quick and lasting recovery. Drug toxicity and
the emergence of resistance could also be dramatically reduced compared with present
long-term monotherapy. Immunotherapy could be an effective addition to chemotherapy
for leishmaniasis.
© 2009 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All
mmunocompromised
mmunostimulation
Leishmaniasis is caused by the Leishmania genus of
rotozoan parasites, and manifests in various forms:
elf-healing or chronic cutaneous leishmaniasis [CL, or
ost-kala-azar dermal leishmaniasis (PKDL)]; debilitating
ucosal leishmaniasis (ML); and fatal (if not treated)
isceral leishmaniasis (VL). The natural history of leish-
aniasis is depicted in Figure 1 in a simpliﬁed schematic
odel applicable to VL and some forms of CL, with the
ssumption that there is a direct relationship between par-
site load and disease. In an immunocompromised host the
isease returns upon stopping treatment (Figure 1A). In
ured or asymptomatically infected individuals, fulminat-
ng disease appears after immunosuppressive drugs or HIV
nfection. However, strong immunity is developed follow-
ng successful recovery in immunocompetent individuals
Figure 1B). Hence the protective immune response is an
mportant part of recovery from leishmaniasis.
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The available treatment options are far from satisfac-
tory as they are either expensive (amphotericin B) or toxic
(antimonials), or resistant parasites have either emerged
or are imminent withmonotherapy (miltefosine and paro-
momycin). One solution is to combine these drugs to
allow shorter, less toxic and more affordable treatment.
This approach is being addressed by WHO, the Drugs
for Neglected Diseases initiative and their endemic coun-
try partners. Another approach is immunochemotherapy,
whereby a low-dose or short course of an effective drug
(possibly one dose of amphotericin B) is given with one
injection of a vaccine or immunomodulator to quickly
induce the effector immune response (Figure 1C).
Immunotherapy was pioneered and used in thousands
of CL and a few ML patients by Convit et al. in Venezuela.1
Machado-Pinto et al. showed a highly signiﬁcant cure rate
for CL using Mayrink’s vaccine (Biobras, Montes Claros,
Brazil) plus a low dose of antimonials, with far fewer
side effects of myalgia, severe pain at the site of injection,
nausea, vomiting, headache, joint pain, etc. than associated
with full doses of antimonials.2 This vaccine has also been
ygiene. Published by Elsevier Ltd. All rights reserved.
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Figure 1. Schematic representation of chemotherapy plus immunother-
apy in leishmaniasis. (A) Immunocompromised hosts. Chemotherapy
reducesparasite loadand induces short-termcure, but in theabsenceof an
effector immune response, patients ultimately relapse and require main-
tenance treatment. (B) Immunocompetent patients. Treatment induces
initial cure and the host’s immune response maintains parasites under
control. Long-lasting immunity is maintained as long as the host remains
immunocompetent. (C) Immunochemotherapy in immunocompetent
patients or immunocompromised patients with a certain minimum
immunocompetence (after antiviral therapy inHIV-Leishmania coinfected
individuals). Immunotherapy just after chemotherapy would induce an
immune response sooner than inB above, reducing theneed for long-term
chemotherapy. This would reduce drug-related toxicity and the emer-
gence of resistant parasites. Solid red line: parasite load; broken blue line:
effector immune response; small black arrows: duration of chemother-
apy. Themore prominent broken blue line in part C indicates the response
induced by immunotherapy in contrast to that naturally induced by the
host, shown in part B.
used in some cases of HIV-Leishmania coinfection in Brazil.
Musa et al. used alum-autoclaved L. major plus BCG (Razi
Institute, Iran) in a preliminary trial involving 30 refrac-
tory PKDL patients, and showed immunochemotherapy
to be superior to chemotherapy (ﬁnal cure rates 100% vs.
40%, P<0.004).3 Chronic cases (>6months) are difﬁcult
to treat with drugs alone, and are considered to be an
important reservoir of infection. Badaro and colleagues
used a mixture of deﬁned recombinant antigens and an
adjuvant (granulocyte-macrophage colony-stimulating
factor) plus antimony to treat refractory ML patients
successfully in a preliminary trial.4 Combining IFN- and
antimony were shown to be effective in the treatment of
some VL and diffuse CL patients in Brazil.5 No vaccine is
available, but these observations are proof of the principle
that immunostimulation is a valid approach in need of
further investigation, andmay be applicable to most forms
of leishmaniasis, including HIV-Leishmania coinfection
under certain conditions.
The mechanism involved is not fully understood. How-
ever, in PKDL lesions there is an inﬂux of  T cells, but
diminution of CD1a (Langerhans) cells. It seems that even
in the presence of effector Th1 cells, parasites are not killed
and lesions persist. Even IFN- treatment does not cure
all patients with leishmaniasis. This may be because of
down-regulation of B7-1 and up-regulation of B7-2 by IL-
10,which leads toapredominantlyTh2 response.6 It should
be noted that a minority of PKDL patients attained cure
without showing a pure Th1 response.ropical Medicine and Hygiene 104 (2010) 1–2
As vaccination has a long-lasting effect and most
drugs work quickly, it may be possible to introduce
immunotherapy at the onset of chemotherapy. How-
ever, the best time must be studied in different forms
of the disease, and in combination with different
drugs.
Immunochemotherapy would have advantages over
secondary chemoprophylaxis (maintenance therapy) for
patients with HIV-Leishmania coinfection, once antiretro-
viral treatment had boosted their immune response to a
certain level.
In all studies except Badaro’s,4 ﬁrst-generation vaccines
(FGV; killed promastigotes of different Leishmania spp.)
were used. These are inexpensive (less than US$1.0/dose),
but they do not meet the current requirements for new
vaccines, and except for Venezuela, limited batches were
produced for trials and they are not available commer-
cially. Nevertheless, the experience gained from testing
them in humans has paved the way for novel approaches
to treatment. Despite failing to induce adequate prophy-
lactic immunity in healthy individuals, FGVs were able to
enhance recovery; possibly because, as shown inmice, dif-
ferent effectormechanismsmaybe involved inprophylaxis
(CD4, Th1) and recovery (CD8).
With well-deﬁned second-generation vaccines being
developed, and well-characterized adjuvants now avail-
able or being tested for other diseases, notably cancers,
immunochemotherapy should be considered as an alterna-
tive modality for the treatment of leishmaniasis, including
HIV-Leishmania coinfection, PKDL and chronic refractory
CL, the forms that are difﬁcult to treat with available drugs.
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